Ceftolozane/tazobactam (Zerbaxa®)

Assessment Status Rapid Review complete
Drug Ceftolozane/tazobactam
Brand Zerbaxa®
Indication For the treatment of complicated urinary tract infections (cUTI), acute pyelonephritis and complicated intra-abdominal infections (cIAI) in adults.
Assessment Process
Rapid review commissioned 03/03/2016
Rapid review completed 26/04/2016
Rapid review outcome Full Pharmacoeconomic Evaluation recommended at the Submitted Price.

September 2016

The HSE has approved reimbursement following confidential price negotiations.